IASLC North America 2019

Complete Coverage

Two New Radiomics Features Predict Lung Cancer Survival in LDCT Screening

Screening patients with lung cancer using low-dose computed tomography (LDCT) has been associated with reducing lung cancer mortality as much as 20%, but the technique remains limited.

Low-Dose Computed Tomography Used to Screen First Responders for Lung Cancer

Occupational exposure account for 30% of all lung cancer diagnosis in the United States.

Genomic Assay Shows Utility in Selecting NSCLC Patients for Targeted Therapy

Next-generation sequencing of circulating tumor DNA (ctDNA) may identify patients who are likely to benefit from targeted therapy for NSCLC.

KRAS-Mutant NSCLC Exhibits Different Genetic, Molecular Characteristics Across Racial Groups

Researchers found that molecular profiles of patients with KRAS-mutant NSCLC differ among patients from various racial groups.

EGFR-Positive Lung Cancer Diagnosis and Patient Quality of Life

Cost of therapy was a major concern among a majority (69%) of patients with lung cancer who responded to the survey.

Risk Model Predicts Survival in NSCLC Patients Treated with Immunotherapy

Researchers identified and validated novel risk groups models that predict OS and PFS among NSCLC patients treated with immunotherapy.

Pneumonitis and Survival Outcomes in Patients With NSCLC Treated With Durvalumab

Researchers examined real-life outcomes with the PACIFIC paradigm and found that the higher incidence of pneumonitis did not affect overall survival.

Assessing the Gut Microbiome of Patients With Lung Cancer Receiving Immunotherapy

Researchers also found differences in the composition of the gut microbiome between patients with lung cancer who experienced toxicity and those who did not.

Personalized Counseling at Lung Cancer Screenings Helps Patients Quit Smoking

Point-of-service counseling in a lung cancer screening program led some patients to quit and many patients to reduce their cigarette usage.

Capmatinib Treats Brain Metastases in NSCLC With MET Exon-14 Skipping Mutation

Researchers observed 4 patients whose brain lesions were completely resolved by treatment with capmatinib.

AMG 510 Well Tolerated by Patients With NSCLC

A phase 1 trial found that AMG 510 is tolerated in patients with previously treated non-small cell lung cancer.

Neutrophil Lymphocyte Ratio May Predict Lung Cancer Overall Survival

Researchers found that NLR before treatment was significantly associated with overall survival and progression-free survival.

Flu Vaccine Does Not Increase Risk of Adverse Events in Patients With Lung Cancer

A retrospective analysis supports the administration of flu vaccination in patients with lung cancer on ICI therapy.

Circulating Autoantibodies Could Predict Patient Response to Immunotherapy

Researchers found that IMP2, a cancer autoantibody, was significantly associated with time to progression in patients with NSCLC treatment with non-frontline PD-1/PD-L1.

Pembrolizumab Improves Survival in NSCLC When Combined With Chemotherapy

Researched conducted a post hoc pooled analysis of 3 KEYNOTE cohorts and found the addition of pembrolizumab improved OS and PFS in patients with NSCLC.